Fujifilm’s New Imaging Option Can Enhance Accuracy of Breast Biopsy

Fujifilm’s New Imaging Option Can Enhance Accuracy of Breast Biopsy
Fujifilm Medical Systems USA has expanded its breast cancer imaging toolbox by releasing a new tomosynthesis option for its ASPIRE Cristalle mammography technology, which improves accuracy of breast biopsy. The new Tomosynthesis Biopsy solution determines the three-dimensional coordinates of a suspicious lesion in the breast. According to Fujifilm, this will improve doctors' ability to locate a lesion and remove it through biopsy for examination. Fujifilm representatives showcased the new system at the Association for Medical Imaging Management (AHRA) 2019 meeting July 21–24 in Denver. "Fujifilm is committed to empowering clinicians to detect breast cancer at its earliest stage, to help save lives through early intervention," Rick Banner, director of marketing at Fujifilm Medical Systems, said in a press release. Breast tomosynthesis, also called digital breast tomosynthesis (DBT), is an advanced form of breast imaging, or mammography, that uses a low-dose X-ray system and digital reconstruction
Subscribe or to access all post and page content.